Lanean...
Reimbursement of licensed cell and gene therapies across the major European healthcare markets
OBJECTIVE: The aim of this research is to identify the pricing, reimbursement, and market access (P&R&MA) considerations most relevant to advanced therapy medicinal products (ATMPs) in the Big5EU, and to inform their manufacturers about the key drivers for securing adoption at a commercially...
Gorde:
| Argitaratua izan da: | J Mark Access Health Policy |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Co-Action Publishing
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4802687/ https://ncbi.nlm.nih.gov/pubmed/27123175 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v3.29321 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|